Clinical trial NCT04046328: Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome
Official title: A Phase IIa, Proof of Concept, Randomized, Double-Blind, Dose-Finding, Cross-Over Study of the Efficacy, Safety and Tolerability of a New Enteric-Coated Cholestyramine Capsule in Adult Short Bowel Syndrome Patients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Short Bowel Syndrome
Lead sponsor: Pharmascience Inc.
Sponsor class: INDUSTRY
First posted: 2019-08-06
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Multiple-center, randomized, double-blind, double dummy, 2-period, 2-sequence cross-over design
Primary purpose: TREATMENT

Brief summary: A new Enteric-Coated Cholestyramine (ECC) capsule has been developed to manage diarrhea associated with Short Bowel Syndrome (SBS) in adults. The formulation is expected to release cholestyramine in the remaining segment of the small intestine in SBS patients, thus binding bile acids after fat digestion, but before induction of diarrhea in the colon. The delayed-release profile is also expected to help reduce the potential for drug-drug interactions occurring in the proximal small intestine. Two doses of ECC will be studied for efficacy, safety and tolerability in this Phase IIa trial.

Detailed description: A new Enteric-Coated Cholestyramine (ECC) capsule has been developed to manage diarrhea associated with Short Bowel Syndrome (SBS). SBS is usually caused by the significant resection or loss of function of the ileum, leading to reduced reabsorption of bile acids and subsequent osmotic diarrhea. The new ECC formulation could release cholestyramine in the remaining segment of the small intestine in SBS patients, delivering and binding bile acids before they induce diarrhea in the colon. The proposed advantages of this formulation are: a) to prevent drug-drug interactions in the proximal GI tract, b) to preserve the fat digestive properties of bile acids in the duodenum and 3) to offer a more palatable dosage form to patients. Moreover, since distal delivery of cholestyramine is expected to be more effective in diarrhea prevention/reduction in SBS, lower doses than the ones used with non-enteric coated cholestyramine may be sufficient. Two doses of ECC will be studied for efficacy, safety and tolerability in well-defined non fully-colectomized, adult SBS patients suffering from diarrhea.

Eligibility criteria: Inclusion Criteria:

1. Adult, ambulatory male and female subjects
2. Provision of signed and dated informed consent form (ICF)
3. Age ≥ 18 years and ≤ 80 years
4. Stable SBS of:

   1. Non-surgical origin; OR
   2. Surgical origin where the last surgical ileal resection was performed at least 6 months prior to enrolment
5. Partial, Home Parenteral Nutrition and/or parenteral fluids are allowed, at a maximum frequency of 6 times a week throughout the trial, as long as the regimen has been stable for at least 2 weeks prior to screening and is expected to remain unchanged during the study
6. At least 50 % of the colon being intact
7. Intact duodenum
8. BMI ≥ 18
9. Presence of stable chronic diarrhea for at least 3 months prior to enrolment as evidenced by medical history
10. Presence of stable chronic diarrhea during the 2-week screening diary period before randomization, as evidenced by completion of a screening diary demonstrating:

    1. Mean daily production of at least 3 soft or watery stools (BSFS scores 6 or 7); or
    2. More than 3 bowel movements per day on average with \>25% of them being BSFS type 6 or 7
11. Stated willingness and ability to comply with all study procedures, including daily recording of bowel movements and BSFS in the patient diaries, and availability for the duration of the study
12. Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without clinical significance, as determined by the investigator
13. Female subjects must meet one of the following criteria:

    a) Participant is of childbearing potential and agrees to use one of the accepted contraceptive regimens from at least 30 days prior to the first study treatment administration through to at least 30 days after the last dose of the study treatment. An acceptable method of contraception includes one of the following:
    1. Abstinence from heterosexual intercourse
    2. Systemic contraceptives (combined birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch)
    3. Intrauterine device (with or without hormones)
    4. Condom with spermicide

    b) Participants of non-childbearing potential, defined as surgically sterile (i.e. has undergone complete hysterectomy or bilateral oophorectomy) or is in a menopausal state (i.e. at least 1 year without menses prior to the first study drug administration) are eligible

Exclusion Criteria:

1. Patients with known or suspected intestinal strictures of clinical relevance as judged by the Investigator
2. Active inflammatory bowel disease (IBD) or fistula during the screening period as judged by the Investigator
3. Crohn's disease patients not being in clinical remission for the last 12 weeks prior to randomization
4. Diarrhea caused by other causes than SBS
5. Presence of clinically significant steatorrhea, requiring pancreatic enzymes supplementation
6. Presence of complete biliary obstruction
7. Presence of active cancer (except resected cutaneous basal or squamous cell carcinoma and except in situ cervical cancer) and/or need to receive chemotherapy or radiotherapy during the study
8. History of allergic reaction to cholestyramine or any excipient of the investigational drug product or placebo, or packaging components
9. Females who are lactating at screening
10. Females who are pregnant according to the pregnancy test at screening or prior to the first study treatment administration
11. Significant history (at least 3 consecutive months in the year prior to Screening) of drug dependency or alcohol abuse (\> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
12. Subjects who took an Investigational Product (IP) in the 30 days prior to the first study drug administration
13. Any other clinically significant condition that is considered by the principal investigator as being susceptible to put the patient at greater safety risk, influence response to study product, or interfere with study assessments.

Primary outcomes:
measure: Change in the Weekly Frequency of Bowel Movements Measured Between Baseline and the Second Week of Treatment
timeFrame: Baseline and Week 2 of treatment (Days 8 to 14, and Days 36 to 42)
Secondary outcomes:
measure: Total Number of Bowel Movements for the Whole 2-week Treatment Period
timeFrame: Days 1 to 14 and Days 29 to 42
measure: Mean Daily Stool Form Score According to the BSFS (Bristol Stool Form Scale), Measured During the Second Week of Treatment
timeFrame: Days 8 to 14, and Days 36 to 42
measure: Mean Daily Dose of Loperamide in mg, if Used, During the Second Week of Treatment
timeFrame: Days 8 to 14, and Days 36 to 42
Other outcomes:
Locations:
city: Poznań
country: Poland
facility: Solumed Centrum Medyczne
city: Skawina
country: Poland
facility: Szpital Wielospecjalistyczny im. Stanleya Dudricka
city: Łódź
country: Poland
facility: Wojewódzki Specjalistyczny Szpital im. M. Pirogowa w Łodzi
Study officials:
affiliation: Wojewódzki Specjalistyczny Szpital im. M. Pirogowa w Łodzi
name: Marek Kunecki, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Solumed Centrum Medyczne
name: Konrad Matysiak, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Szpital Wielospecjalistyczny im. Stanleya Dudricka
name: Kinga Szczepanek, MD
role: PRINCIPAL_INVESTIGATOR
References: